Characterization of Prescription Opioid Abuse in the United States: Focus on Route of Administration

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Pain & Palliative Care Pharmacotherapy

• Publication date

  2012-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/15360288.2012.734905PMID 23675595
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Relationship between rate of infusion and reinforcing strength of oxycodone in humans.

  2018cited by this paper
• About the Web Site

  2013cited by this paper
• Effects of reformulated OxyContin® among patients assessed for substance abuse treatment in the NAVIPPRO sentinel surveillance network

  2012cited by this paper
• Opioid extended-release tablets with improved tamper-resistant properties

  2012cited by this paper
• Separate and combined psychopharmacological effects of alprazolam and oxycodone in healthy volunteers.

  2012cited by this paper
• Initiation into prescription opioid misuse amongst young injection drug users.

  2012cited by this paper
• OPIOIDS, SUBSTANCE ABUSE & ADDICTIONS SECTION Original Research Article A History of Being Prescribed Controlled Substances and Risk of Drug Overdose Death

  2012cited by this paper
• A history of being prescribed controlled substances and risk of drug overdose death.

  2012cited by this paper
• Health plan implementation of U.S. Preventive Services Task Force A and B recommendations--Colorado, 2010.

  2011cited by this paper
• Characteristics and correlates of men and women with prescription opioid dependence.

  2011cited by this paper
• Attitudes of Florida Pharmacists Toward Implementing a State Prescription Drug Monitoring Program for Controlled Substances

  2011cited by this paper
• Current status and evolving role of abuse-deterrent opioids in managing patients with chronic pain.

  2011cited by this paper
• Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008.

  2011cited by this paper
• Issues and critiques of the forthcoming risk evaluation and mitigation strategy (REMS) for opioids in pain management.

  2011cited by this paper
• Alternate Routes of Administration and Risk for HIV Among Prescription Opioid Abusers

  2011cited by this paper
• The abuse potential of Remoxy(®), an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone.

  2011cited by this paper
• Tamper-resistant properties of once-daily hydromorphone ER (OROS hydromorphone)

  2011cited by this paper
• Definitions related to the use of pharmaceutical opioids: extramedical use, diversion, non-adherence and aberrant medication-related behaviours.

  2011cited by this paper
• Abuse-Deterrent and Tamper-Resistant Opioid Formulations

  2010cited by this paper
• Measuring attractiveness for abuse of prescription opioids.

  2010cited by this paper
• Evaluation of the Abuse Potential of Extended Release Hydromorphone Versus Immediate Release Hydromorphone

  2010cited by this paper
• Reducing the Abuse Potential of Controlled Substances

  2010cited by this paper
• Route of administration for illicit prescription opioids: a comparison of rural and urban drug users

  2010cited by this paper
• The Food and Drug Administration Risk Evaluation and Mitigation Strategy

  2010cited by this paper
• Characteristics of prescription opioid abusers in treatment: prescription opioid use history, age, use patterns, and functional severity.

  2010cited by this paper
• Opioid formulations in development designed to curtail abuse: who is the target?

  2009cited by this paper
• Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006.

  2009cited by this paper
• Opioid deaths in rural Virginia: a description of the high prevalence of accidental fatalities involving prescribed medications.

  2009cited by this paper
• Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.

  2009cited by this paper
• Abuse-deterrent opioid formulations: Are they a pipe dream?

  2008cited by this paper
• Patterns of abuse among unintentional pharmaceutical overdose fatalities.

  2008cited by this paper
• Internet-based Survey of Nonmedical Prescription Opioid Use in the United States

  2008cited by this paper
• What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review.

  2008cited by this paper
• Abuse of medications employed for the treatment of ADHD: results from a large-scale community survey.

  2008cited by this paper
• Motives, diversion and routes of administration associated with nonmedical use of prescription opioids.

  2007cited by this paper
• Do Formulation Differences Alter Abuse Liability of Methylphenidate?: A Placebo-Controlled, Randomized, Double-Blind, Crossover Study in Recreational Drug Users

  2007cited by this paper
• Challenges in the Development of Prescription Opioid Abuse-deterrent Formulations

  2007cited by this paper
• Providing Constant Analgesia with OROS® Hydromorphone

  2007cited by this paper
• Prescription OxyContin abuse among patients entering addiction treatment.

  2007cited by this paper
• PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate.

  2006cited by this paper
• Letter to the Editor—Comparison of Fentanyl Extraction from Two Different Transdermal Patches

  2006cited by this paper
• Overview of Oral Modified-Release Opioid Products for the Management of Chronic Pain

  2006cited by this paper
• Abuse of prescription drugs and the risk of addiction.

  2006cited by this paper
• Psychiatrie and Pain Characteristics of Prescription Drug Abusers Entering Drug Rehabilitation

  2006cited by this paper
• Subjective and behavioral effects of diazepam depend on its rate of onset

  2005cited by this paper
• The controversy surrounding OxyContin abuse: issues and solutions

  2005cited by this paper
• Drug crime is a source of abused pain medications in the United States.

  2005cited by this paper
• A Profile of OxyContin Addiction

  2004cited by this paper
• Definitions related to the medical use of opioids: evolution towards universal agreement.

  2003cited by this paper
• Behavioral Monitoring and Urine Toxicology Testing in Patients Receiving Long-Term Opioid Therapy

  2003cited by this paper
• Oxycodone involvement in drug abuse deaths: a DAWN-based classification scheme applied to an oxycodone postmortem database containing over 1000 cases.

  2003cited by this paper
• Health, United States 2003: With Chartbook on Trends in the Health of Americans

  2003cited by this paper
• Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans.

  2001cited by this paper
• Prevalence of opioid abuse in interventional pain medicine practice settings: a randomized clinical evaluation.

  2001cited by this paper
• Prescription opiate abuse in chronic pain patients: clinical criteria, incidence, and predictors.

  1997cited by this paper
• Alprazolam absorption kinetics affects abuse liability *

  1995cited by this paper

• Oxytocin Attenuates Yohimbine-Induced Responding for Oral Oxycodone under a Progressive Ratio Schedule in Male and Female Rats.

  2025cites this paper
• The Prevalence, Chronology, and Clinical Correlates of Traumatic Brain Injury Among Individuals Seeking Treatment for Opioid Use Disorder.

  2025cites this paper
• Review on Recent Development in Opioid Abuse-Deterrent Formulation Technologies and Regulatory Expectation

  2024cites this paper
• ADOLESCENT ORAL OXYCODONE SELF-ADMINISTRATION DISRUPTS NEUROBEHAVIORAL AND NEUROCOGNITIVE DEVELOPMENT.

  2024cites this paper
• Differential etiologic associations of heroin use and prescription opioid misuse with psychopathology.

  2024cites this paper
• Medicaid expansion and medications to treat opioid use disorder in outpatient specialty care from 2010 to 2020.

  2024cites this paper
• Exploring racial and secondary substance use differences in route of administration of opioid drugs: Analysis of the 2015-2019 treatment admission data.

  2024cites this paper
• Oral fentanyl consumption and withdrawal impairs fear extinction learning and enhances basolateral amygdala principal neuron excitatory-inhibitory balance in male and female mice

  2023cites this paper
• Advancement in Opioid Abuse-deterrent Formulation Technologies and Regulatory Expectation.

  2023cites this paper
• Current status of opioid prescription in South Korea using narcotics information management system

  2023cites this paper
• Chronic Voluntary Morphine Intake Is Associated with Changes in Brain Structures Involved in Drug Dependence in a Rat Model of Polydrug Use

  2023cites this paper
• All Hands on Deck: We Need Multiple Approaches To Uncover the Neuroscience behind the Opioid Overdose Crisis.

  2023cites this paper
• Oral oxycodone self-administration leads to features of opioid addiction in male and female mice

  2022cites this paper
• A Novel Morphine Drinking Model of Opioid Dependence in Rats

  2022cites this paper
• Oral oxycodone self‐administration leads to features of opioid misuse in male and female mice

  2022cites this paper
• Fentanyl in Pressed Oxycodone Pills: A Qualitative Analysis of Online Community Experiences with an Emerging Drug Trend

  2022cites this paper
• The effect of concurrent access to alcohol and oxycodone on self-administration and reinstatement in rats

  2022cites this paper
• The effects of opioid policy changes on transitions from prescription opioids to heroin, fentanyl and injection drug use: a qualitative analysis

  2022cites this paper
• Substance Abuse

  2021cites this paper
• Modeling features of addiction with an oral oxycodone self-administration paradigm

  2021cites this paper
• A limited access oral oxycodone paradigm produces physical dependence and mesocorticolimbic region-dependent increases in DeltaFosB expression without preference.

  2021cites this paper
• Adenosine Monophosphate-activated Protein Kinase (AMPK) in serotonin neurons mediates select behaviors during protracted withdrawal from morphine in mice.

  2021cites this paper
• Remote local photoactivation of morphine produces analgesia without opioid‐related adverse effects

  2021cites this paper
• Developing an animal model to detect drug–drug interactions impacting drug-induced respiratory depression

  2020cites this paper
• Patterns of Routes of Administration and Drug Tampering for Nonmedical Opioid Consumption: Data Mining and Content Analysis of Reddit Discussions

  2020influential citation
• Using contact-based education to destigmatize opioid use disorder among medical students

  2020cites this paper
• Abuse deterrent immediate release film technology (ADRIFT): A novel bilayer film technology for limiting intentional drug abuse.

  2020cites this paper
• Finding the Hidden Risk Profiles of the United States Opioid Epidemic: Using a Person-Centered Approach on a National Dataset of Noninstitutionalized Adults Reporting Opioid Misuse

  2020cites this paper
• The opioid mortality epidemic in North America: do we understand the supply side dynamics of this unprecedented crisis?

  2020cites this paper
• Oral prescription opioid-seeking behavior in male and female mice

  2019influential citation
• Sex differences in oral oxycodone self‐administration and stress‐primed reinstatement in rats

  2019cites this paper
• Changes in Reported Injection Behaviors Following the Public Health Response to an HIV Outbreak Among People Who Inject Drugs: Indiana, 2016

  2019cites this paper
• Human Abuse Potential of Oral NKTR-181 in Recreational Opioid Users: A Randomized, Double-Blind, Crossover Study

  2019cites this paper
• Drug Abuse Prediction Model Based on Relevance Analysis

  2019cites this paper
• Pain and Opioid Management Resources

  2018cites this paper
• What’s holding back abuse-deterrent opioid formulations? Considering 12 U.S. stakeholders

  2018cites this paper
• The effect of quinine in two bottle choice procedures in C57BL6 mice: Opioid preference, somatic withdrawal, and pharmacokinetic outcomes.

  2018cites this paper
• Repeat Infective Endocarditis in Persons Who Inject Drugs: “Take Another Little Piece of my Heart”

  2018cites this paper
• Opioid Knowledge and Prescribing Practices Among Obstetrician-Gynecologists.

  2017cites this paper
• Prescription Opioid Abuse in Chronic Pain: An Updated Review of Opioid Abuse Predictors and Strategies to Curb Opioid Abuse: Part 1.

  2017cites this paper
• The Evolution of Abuse-Deterrent Extended-Release Opioid Formulations: Is there a Place in the Armamentarium for More Products?

  2017cites this paper
• Variability in prescription opioid intake and reinforcement amongst 129 substrains

  2017cites this paper
• Trends in Narcotic and Corticosteroid Prescriptions in Patients with Inflammatory Bowel Disease in the United States Ambulatory Care Setting from 2003 to 2011

  2017cites this paper
• Abuse-related Behavioral Effects of Oxycodone in the Mouse and their Modulation by HIV-1 Tat Expression

  2017influential citation
• Small-Town America’s Despair: Infected Substance Users Needing Outpatient Parenteral Therapy and Risk Stratification

  2017cites this paper
• Substance Abuse: Drugs

  2016cites this paper
• Substance Abuse Issues in Oncology: What the ED Professional Needs to Know

  2016cites this paper
• Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain.

  2016cites this paper
• Oxycodone physical dependence and its oral self-administration in C57BL/6J mice.

  2016cites this paper
• Medical Judgments Across the Range of Reported Pain Severity: Clinician and Lay Perspectives.

  2016cites this paper
• Predictors of transition to heroin use among initially non-opioid dependent illicit pharmaceutical opioid users: A natural history study.

  2016cites this paper
• Abuse-Deterrent Opioid Formulations: Pharmacokinetic and Pharmacodynamic Considerations

  2016cites this paper
• Scope of the Problem: Intersection of Chronic Pain and Addiction

  2016cites this paper
• Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations

  2016cites this paper
• Emerging factors in the progression of cancer-related pain.

  2016cites this paper
• Hair testing in postmortem diagnosis of substance abuse: An unusual case of slow-release oral morphine abuse in an adolescent.

  2015cites this paper
• Routes of Opioid Abuse and its Novel Deterrent Formulations

  2015cites this paper
• Prescription opioids. III. Disposition of oxycodone in oral fluid and blood following controlled single-dose administration.

  2015cites this paper
• Associations between prescription opioid injection and Hepatitis C virus among young injection drug users

  2015cites this paper
• The role of abuse‐deterrent formulations in countering opioid misuse and abuse

  2015cites this paper
• Prescription Opioids. IV: Disposition of Hydrocodone in Oral Fluid and Blood Following Single-Dose Administration.

  2015cites this paper
• Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO‐02, an extended release formulation of oxycodone with sequestered naltrexone

  2015cites this paper
• Dynamic model of nonmedical opioid use trajectories and potential policy interventions

  2015cites this paper
• Effect of both preoperative andpostoperative cryoceutical treatment on hemostasis and postoperative pain following total knee arthroplasty.

  2015cites this paper
• Drug Use, Hepatitis C, and Service Availability: Perspectives of Incarcerated Rural Women

  2015cites this paper
• Drugs of Abuse

  2015cites this paper
• High-risk use by patients prescribed opioids for pain and its role in overdose deaths.

  2014cites this paper
• Oxycodone/Naloxone: Role in Chronic Pain Management, Opioid-Induced Constipation, and Abuse Deterrence

  2014cites this paper
• Primary and secondary prevention of hepatitis C virus among rural appalachian people who use drugs

  2014cites this paper
• Technology-Assisted Addiction Treatment for Key Populations

  2014cites this paper
• Effectiveness and tolerability of low-dose oral oxycodone/naloxone added to anticonvulsant therapy for noncancer neuropathic pain: an observational analysis

  2014cites this paper
• Update on extended-release opioids in pain management

  2014cites this paper
• Appropriate experimental approaches for predicting abuse potential and addictive qualities in preclinical drug discovery

  2014cites this paper
• Substance Abuse in Oncology

  2014cites this paper
• Prescribe opioids for chronic non-cancer pain with care for the sake of patients and the community

  2013cites this paper
• [Abuse-related adverse drug reactions and abuse deterrent formulations].

  2013cites this paper
• Reacciones adversas de medicamentos relacionadas con el abuso y formas farmacéuticas disuasorias

  2013cites this paper